Category: Pharmaceuticals

Pharmaceuticals

Incannex Secures US Patent for Sleep Apnea Drug Candidate IHL-42X

The granted patent protects the proprietary oral combination therapy through at least 2040, as the company prepares to launch its Phase 2 dose optimization study.

Pharmaceuticals

Eli Lilly Completes Acquisition of Centessa Pharmaceuticals to Advance Narcolepsy Treatments

Eli Lilly and Company has completed its acquisition of Centessa Pharmaceuticals, securing a portfolio of clinical-stage orexin receptor 2 agonists. This strategic move aims to accelerate the development of new treatments for narcolepsy and other sleep-wake disorders.

Pharmaceuticals

Natrol Launches Ultra Sleep and Ultra Energy Supplements, Partners with Calm

The new dual-product system aims to support the 24-hour wellness cycle, accompanied by a strategic partnership with the Calm app to offer curated sleep content.

Prescription Drugs

Jazz Pharmaceuticals to Present Xywav Narcolepsy Data at 2026 AAN Annual Meeting

New poster presentation will detail self-reported outcomes in patients with narcolepsy treated with high dosages of low-sodium oxybate in the DUET study.

Over-the-Counter Treatments

Saline Nasal Spray Shows Efficacy in Treating Pediatric Sleep-Disordered Breathing

A new Australian study finds that a simple saline nasal spray can resolve symptoms of obstructive sleep-disordered breathing in children, potentially reducing the need for surgery and specialist care.

Emerging Compounds

Apnimed Secures Up to $150 Million to Support Planned Commercial Launch of AD109

The financing will fund commercial readiness for the investigational oral obstructive sleep apnea therapy ahead of an anticipated new drug application.